Small molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer
T Cascone1, M P Morelli, F Ciardiello
1Cattedra di Oncologia Medica, Dipartimento Medico-Chirurgico di Internistica Clinica e Sperimentale F. Magrassi e A. Lanzara, Seconda Università degli Studi di Napoli, Napoli, Italy.
Abstract:
Despite recent developments in the diagnosis and conventional treatment of non small cell lung cancer (NSCLC), the prognosis remains unsatisfactory, with 5-year survival rates of approximately 15% for all stages. To date, chemotherapy represents the standard treatment for advanced-non small lung cancer, but efficacy of currently available cytotoxic drugs is modest. Median survival does not exceed 8-10 months. New treatment strategies are needed and considerable hope has been placed in therapies that specifically target the molecular mechanisms of tumour growth. One molecular target of particular relevance to lung cancer pathogenesis is the epidermal growth factor receptor (EGFR), a cell membrane receptor tyrosine kinase. Several inhibitors of EGFR fuctinonal activation have been developed. Amon these, erlotinib (Tarceva) and gefitinib (Iressa) are two orally bioavailable, small molecule EGFR inhibitors of the tyrosine kinase enzymatic activity which prevent EGFR autophosphorylation and activation. In monotherapy, gefitinib and erlotinib have determinated a 10-20% response rate and a 30-50% symptom improvement in previously treated, chemotherapy refractory, advanced NSCLC patients. Furthermore, a randomized, placebo controlled, multicenter phase III study has shown a two months improvement in median survival with erlotinib in the second or third line treatment of metastatic NSCLC patients. We will summarize the clinical evidence on the anticancer activity of small molecule EGFR inhibitors.
Insights
New targeted therapies, including epidermal growth factor receptor (EGFR) inhibitors like erlotinib and gefitinib, show promise for advanced non-small cell lung cancer (NSCLC) patients refractory to chemotherapy.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Non-small cell lung cancer (NSCLC) has a poor prognosis despite advances in diagnosis and conventional chemotherapy.
- Current chemotherapy for advanced NSCLC offers modest efficacy, with median survival around 8-10 months.
- Targeting molecular mechanisms of tumor growth is a critical area for developing novel NSCLC therapies.
Purpose of the Study:
- To review the clinical evidence on the anticancer activity of small molecule epidermal growth factor receptor (EGFR) inhibitors.
- To highlight the role of EGFR as a molecular target in lung cancer pathogenesis.
- To summarize the efficacy of EGFR inhibitors in advanced NSCLC.
Main Methods:
- Review of clinical evidence on small molecule EGFR inhibitors.
- Summary of data from monotherapy and phase III studies.
- Focus on erlotinib and gefitinib as examples of EGFR inhibitors.
Main Results:
- Gefitinib and erlotinib demonstrated 10-20% response rates and 30-50% symptom improvement in chemotherapy-refractory advanced NSCLC patients.
- A phase III study showed a two-month improvement in median survival with erlotinib in second or third-line treatment.
- These small molecule inhibitors target the tyrosine kinase activity of EGFR, preventing its activation.
Conclusions:
- Small molecule EGFR inhibitors represent a promising therapeutic strategy for advanced NSCLC.
- Erlotinib and gefitinib offer clinical benefits, including improved survival and symptom management.
- Targeted therapies focusing on molecular pathways like EGFR are crucial for improving NSCLC outcomes.
More Related Videos
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
13:34A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Published on: April 6, 2016
Related Concept Videos
02:38Mitogens and the Cell Cycle
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
01:27Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
01:26Receptor Tyrosine Kinases
01:00Enzyme-linked Receptors
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...